HOOKIPA Pharma’s Return On Capital Employed Overview
Benzinga Pro data, HOOKIPA Pharma (NASDAQ:HOOK) reported Q4 sales of $3.90 million. Earnings fell to a loss of $21.23 million, resulting in a 5.96% decrease from last quarter.
RBC Capital Maintains Outperform on HOOKIPA Pharma, Lowers Price Target to $9
RBC Capital analyst Brian Abrahams maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and lowers the price target from $11 to $9.
HOOKIPA Pharma: Q4 Earnings Insights
HOOKIPA Pharma (NASDAQ:HOOK) reported its Q4 earnings results on Thursday, March 24, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Earnings Scheduled For March 24, 2022
Companies Reporting Before The Bell
• iHuman (NYSE:IH) is likely to report earnings for its fourth quarter.
HOOKIPA Pharma Earnings Preview
HOOKIPA Pharma (NASDAQ:HOOK) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement.
Analysts estimate that HOOKIPA Pharma will report an earnings per share (EPS) of $-0.58.
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.
How To Attend HOOKIPA Pharma Q4 2021 Earnings Conference Call
HOOKIPA Pharma (NASDAQ:HOOK) will host a conference call at 08:30 AM ET on March 24, 2022, to discuss Q4 2021 earnings results.
How to Attend HOOKIPA Pharma (HOOK) Conference Call
Follow this link to access the live webcast.
HOOKIPA Pharma Highlights Will Present Preclinical Biomarker Data At American Association For Cancer Research Apr. 8-13
Four poster presentations expand evidence on potent T cell responses, ability to break tolerance and potential combination use beyond PD-1 inhibitors
Preclinical data suggest synergy of arenaviral